On November 24, 2020 Kaleido Biosciences, Inc. (Nasdaq: KLDO), reported that Dan Menichella, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference taking place November 30-December 3, 2020 (Press release, Kaleido Biosciences, NOV 24, 2020, View Source [SID1234571663]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available for registered attendees via the Piper Sandler conference site during the conference until December 3, 2020, and will also be available November 30, 2020, on the Investors & Media section of the Kaleido website at View Source An archived replay will be accessible for 90 days following the event.

On November 24, 2020 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that the Company will participate at the Diamond Equity Research Emerging Growth Invitational taking place virtually on December 1, 2020 (Press release, Genprex, NOV 24, 2020, View Source [SID1234571662]). Genprex’s Executive Vice President and Chief Operating Officer, Michael Redman, will virtually deliver a company overview to investors followed by a guided question and answer session.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Diamond Equity Research Emerging Growth Invitational

Date: Tuesday, December 1

Time: 11:40 a.m. EST

Registration Link: https://bit.ly/2UJS3Si

A live audio webcast and archive of the conference presentation will be available for a period of time using the registration link above. For more information on the Diamond Equity Research Emerging Growth Invitational, please contact your Diamond Equity Research representative.

On November 24, 2020 Genmab A/S (Nasdaq: GMAB) reported that it will not advance the development of enapotamab vedotin. While enapotamab vedotin has shown some evidence of clinical activity, this was not optimized by different dose schedules and/or predictive biomarkers (Press release, Genmab, NOV 24, 2020, View Source [SID1234571661]). Accordingly, the data from the expansion cohorts did not meet Genmab’s stringent criteria for proof-of-concept.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are committed to developing innovative antibody products for patients with cancer, however the data from the enapotamab vedotin expansion cohorts unfortunately does not support moving this product candidate forward. This decision will allow us to focus more of our resources and energy on other programs in our robust next-generation antibody therapeutics pipeline," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

About Enapotamab Vedotin
Enapotamab vedotin is an AXL targeted Antibody-Drug Conjugate (ADC) in which the monoclonal antibody is conjugated to the antimitotic drug monomethyl auristatin E. AXL is a signaling molecule overexpressed in several hematologic and solid malignancies. In the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumor angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response. Enapotamab vedotin is fully owned by Genmab and the drug linker technology used for enapotamab vedotin was licensed from Seagen Inc.

On November 24, 2020 Eli Lilly and Company (NYSE: LLY) reported that it will participate in the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020 (Press release, Eli Lilly, NOV 24, 2020, https://investor.lilly.com/news-releases/news-release-details/lilly-participate-evercore-isi-3rd-annual-healthconx-conference [SID1234571660]). Michael Mason, Lilly senior vice president and president of Lilly Diabetes and Connected Care, will participate in a virtual fireside chat at 2:40 p.m., Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s Investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

On November 24, 2020 Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, reported that Steve Hoerter, President and Chief Executive Officer, has participated in a fireside chat in advance of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020 (Press release, Deciphera Pharmaceuticals, NOV 24, 2020, View Source [SID1234571659]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A recording of the fireside chat is now available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source and will be available for 90 days.